BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Heart Failure readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Heart Failure\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03994874-616@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PolyCore: Phase 1/2 readout est. (NCT03994874)
DESCRIPTION:PolyCore\, phase 1/2\, Heart Failure.\nStudy: Peritoneal Ultraf
 iltration in Cardio Renal Syndrome.\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/polycore#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03994874
URL:https://assetmemo.bio/drug/polycore#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820099-186@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT06820099)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Study on th
 e Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejecti
 on Fraction/Preserved Ejection Fraction Heart Failure and Obesity\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06820099
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692256-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07692256)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: th
 e Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07692256
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06122779-597@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Delocamten: Phase 2 readout est. (NCT06122779)
DESCRIPTION:Delocamten\, phase 2\, Heart Failure.\nStudy: Study to Evaluate
  Safety\, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participan
 ts With Heart Failure With Preserved Ejection Fraction (HFpEF)\nEstimated 
 primary completion: 14 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/delocamten#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06122779
URL:https://assetmemo.bio/drug/delocamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265349-613@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HucMSC intramyocardial therapy: Phase 1/2 readout est. (NCT07265349
 )
DESCRIPTION:HucMSC intramyocardial therapy\, phase 1/2\, Heart Failure.\nSt
 udy: A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs f
 or the Treatment of Chronic Heart Failure\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hucm
 sc-intramyocardial-therapy#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07265349
URL:https://assetmemo.bio/drug/hucmsc-intramyocardial-therapy#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669169-639@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jia Shen Tablet: Phase 2 readout est. (NCT06669169)
DESCRIPTION:Jia Shen Tablet\, phase 2\, Heart Failure.\nStudy: Efficacy and
  Safety of Jia Shen Tablets in Chronic Heart Failure\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/jia-shen-tablet#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06669169
URL:https://assetmemo.bio/drug/jia-shen-tablet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443696-653@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:XTR003: Phase 2 readout est. (NCT07443696)
DESCRIPTION:XTR003\, phase 2\, Heart Failure.\nStudy: PET Myocardial Fatty-
 acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocard
 ial Viability in Ischemic Cardiomyopathy\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/xtr00
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 443696
URL:https://assetmemo.bio/drug/xtr003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06304857-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630485
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treate
 d with AnthrAcycline - PROTECTAA TRIAL\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06304857
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05392764-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05392764)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ea
 rly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-ris
 k Patients With Acute Heart Failure\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflo
 zin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05392764
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762964-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0676296
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation\nEstim
 ated primary completion: February 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06762964
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372040-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07372040)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Ad
 d-on Diuretics in Acute Decompensated Heart Failure\nEstimated primary com
 pletion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07372040
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570473-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06570473)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Fe
 asibility Trial for a Right Ventricular Failure Platform Trial\nEstimated 
 primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06570473
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05279742-528@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase 1/2 readout est. (NCT0527974
 2)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 1/2\, Heart Failure.\nS
 tudy: Enhancing the Natriuretic Peptide System in HFpEF\nEstimated primary
  completion: April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacubitril-valsartan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05279742
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712030-528@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT06712030)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3\, Heart Failure.\nStu
 dy: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin 
 Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacubitril-valsartan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06712030
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630765
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With Heart Failure and Impaired Kidney Function\nEstimated primary comp
 letion: 16 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06307652
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-594@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Balcinrenone: Phase 3 readout est. (NCT06307652)
DESCRIPTION:Balcinrenone\, phase 3\, Heart Failure.\nStudy: Study to Evalua
 te the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure
  and Impaired Kidney Function\nEstimated primary completion: 16 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/balcinrenone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06307652
URL:https://assetmemo.bio/drug/balcinrenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038356-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07038356)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ef
 fects of Continued Administration of Empagliflozin in Patients With Heart 
 Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensat
 ed Heart Failure\nEstimated primary completion: 30 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07038356
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979375-598@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270516
DTEND;VALUE=DATE:20270517
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979375)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring CDR132L With Placebo on the Structure and Function of the Heart in 
 People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction an
 d Left Ventricular Hypertrophy\nEstimated primary completion: 16 May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06979375
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138575-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT05138575)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: SG
 LT2i and KNO3 in HFpEF - The SAK HFpEF Trial\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05138575
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07496372-609@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:HiCM-188 (allogeneic iPSC-cardiomyocytes): Phase 3 readout est. (NC
 T07496372)
DESCRIPTION:HiCM-188 (allogeneic iPSC-cardiomyocytes)\, phase 3\, Heart Fai
 lure.\nStudy: A Pivotal Clinical Trial of Human Induced Pluripotent Stem C
 ell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advan
 ced Heart Failure(NYHA III-IV)\nEstimated primary completion: 30 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hicm-188-allogeneic
 -ipsc-cardiomyocytes#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07496372
URL:https://assetmemo.bio/drug/hicm-188-allogeneic-ipsc-cardiomyocytes#upco
 ming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06815471-651@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Corteria COR-1167: Phase 2 readout est. (NCT06815471)
DESCRIPTION:Corteria COR-1167\, phase 2\, Heart Failure.\nStudy: CRF2 Agoni
 st for the Treatment of Worsening Heart Failure\nEstimated primary complet
 ion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/corte
 ria-cor-1167#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06815471
URL:https://assetmemo.bio/drug/corteria-cor-1167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374291-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0537429
 1)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapaglifloz
 in on Renal and Cardiovascular Outcomes in Patients With Severe CKD\nEstim
 ated primary completion: July 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05374291
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736574-593@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Omecamtiv mecarbil: Phase 3 readout est. (NCT06736574)
DESCRIPTION:Omecamtiv mecarbil\, phase 3\, Heart Failure.\nStudy: Study Wit
 h Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Seve
 rely Reduced Ejection Fraction\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/omecamtiv-mecarbi
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 736574
URL:https://assetmemo.bio/drug/omecamtiv-mecarbil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435156-314@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT06435156)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Heart Failure.\nStudy: Sotag
 liflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes\nEsti
 mated primary completion: 31 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06435156
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: A 
 Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Com
 bination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEs
 timated primary completion: November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008197-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06008197)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone on Morbidity and Mort
 ality Among Hospitalized Heart Failure Patients\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 inerenone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06008197
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combina
 tion in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979362-598@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979362)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring Different Doses of CDR132L With Placebo on the Structure and Functi
 on of the Heart in People With Heart Failure With Preserved Ejection Fract
 ion and Left Ventricular Hypertrophy\nEstimated primary completion: 16 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979
 362
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929806-591@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT06929806)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Heart F
 ailure.\nStudy: Multi-center Trial of Ferric Derisomaltose Versus no Intra
 venous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Fail
 ure\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06929806
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469722-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2/3 readout est. (NCT07469
 722)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2/3\, Heart Failure.\
 nStudy: POcus INTERvention for Tailoring Diuretic Strategy in Acute Decomp
 ensated Heart Failure\nEstimated primary completion: 31 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07469722
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646210-609@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:HiCM-188 (allogeneic iPSC-cardiomyocytes): Phase 1/2 readout est. (
 NCT07646210)
DESCRIPTION:HiCM-188 (allogeneic iPSC-cardiomyocytes)\, phase 1/2\, Heart F
 ailure.\nStudy: HiCM-188 Cell Therapy in Adults With Advanced Heart Failur
 e Undergoing Heart Bypass Surgery\nEstimated primary completion: February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/hicm-188-alloge
 neic-ipsc-cardiomyocytes#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07646210
URL:https://assetmemo.bio/drug/hicm-188-allogeneic-ipsc-cardiomyocytes#upco
 ming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-308@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07304817)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Co
 mparative Study on the Mode of Action of Vicadrostat and Spironolactone on
  Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated pr
 imary completion: February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07304817
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-369@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vicadrostat: Phase 2 readout est. (NCT07304817)
DESCRIPTION:Vicadrostat\, phase 2\, Heart Failure.\nStudy: Comparative Stud
 y on the Mode of Action of Vicadrostat and Spironolactone on Protein Profi
 les and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated primary completi
 on: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vi
 cadrostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07304817
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260709-634@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Coramitug: Phase 2 readout est. (NCT06260709)
DESCRIPTION:Coramitug\, phase 2\, Heart Failure.\nStudy: A Research Study t
 o Look at Long-term Treatment With a Medicine Called NNC6019-0001 for Peop
 le Who Have Heart Failure Due to Transthyretin Amyloidosis\nEstimated prim
 ary completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/coramitug#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06260709
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991257-628@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280508
DTEND;VALUE=DATE:20280509
SUMMARY:PF-07328948: Phase 2 readout est. (NCT06991257)
DESCRIPTION:PF-07328948\, phase 2\, Heart Failure.\nStudy: A Study to Learn
  About the Study Medicine Called PF-07328948 in Adults With Heart Failure 
 (BRANCH-HF)\nEstimated primary completion: 8 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pf-07328948#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06991257
URL:https://assetmemo.bio/drug/pf-07328948#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424288-369@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280522
DTEND;VALUE=DATE:20280523
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06424288)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat in Combination With Empagliflozin Helps People With He
 art Failure\nEstimated primary completion: 22 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06424288
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687186-640@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:QiShenYiQi: Phase 3 readout est. (NCT07687186)
DESCRIPTION:QiShenYiQi\, phase 3\, Heart Failure.\nStudy: Qishen Yiqi Dripp
 ing Pills in Treatment of Chronic Heart FailUre\nEstimated primary complet
 ion: 22 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qi
 shenyiqi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07687186
URL:https://assetmemo.bio/drug/qishenyiqi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037459-143@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 59)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced
  Ejection Fraction and Obesity\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07037459
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601465-587@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280716
DTEND;VALUE=DATE:20280717
SUMMARY:Verquvo (Vericiguat): Phase 2 readout est. (NCT06601465)
DESCRIPTION:Verquvo (Vericiguat)\, phase 2\, Heart Failure.\nStudy: COgniti
 oN With VERiciGuat Evaluation in Heart Failure\nEstimated primary completi
 on: 16 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ver
 iciguat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06601465
URL:https://assetmemo.bio/drug/vericiguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584967-663@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:AC01: Phase 2 readout est. (NCT07584967)
DESCRIPTION:AC01\, phase 2\, Heart Failure.\nStudy: A Study to Evaluate the
  Safety and Efficacy of AC01 Compared to Placebo in Participants With Chro
 nic Heart Failure\nEstimated primary completion: 30 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ac01#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07584967
URL:https://assetmemo.bio/drug/ac01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508035-528@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Entresto (Sacubitril/valsartan): Phase 3 readout est. (NCT05508035)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 3\, Heart Failure.\nStu
 dy: The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular
  Function and Remodeling in Patients With Ischemic Heart Failure With Mid-
 range Ejection Fraction\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05508035
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07273838-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0727383
 8)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Car
 diorenal Syndrome\nEstimated primary completion: 31 August 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07273838
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018297-622@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Lasix ONYU (Furosemide (subcutaneous\, SQ Innovation)): Phase 3 rea
 dout est. (NCT07018297)
DESCRIPTION:Lasix ONYU (Furosemide (subcutaneous\, SQ Innovation))\, phase 
 3\, Heart Failure.\nStudy: Early Discharge With Subcutaneous Furosemide Ve
 rsus Standard Care in Acute Heart Failure\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furo
 semide-subcutaneous-sq-innovation#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07018297
URL:https://assetmemo.bio/drug/furosemide-subcutaneous-sq-innovation#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192211-612@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:ADR-002K: Phase 2 readout est. (NCT07192211)
DESCRIPTION:ADR-002K\, phase 2\, Heart Failure.\nStudy: Exploratory Study o
 f ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Unde
 rgo CABG\nEstimated primary completion: 30 September 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/adr-002k#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07192211
URL:https://assetmemo.bio/drug/adr-002k#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471698-609@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:HiCM-188 (allogeneic iPSC-cardiomyocytes): Phase 1/2 readout est. (
 NCT07471698)
DESCRIPTION:HiCM-188 (allogeneic iPSC-cardiomyocytes)\, phase 1/2\, Heart F
 ailure.\nStudy: hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Is
 chemic Heart Disease\nEstimated primary completion: 20 October 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/hicm-188-allogeneic-ipsc-c
 ardiomyocytes#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07471698
URL:https://assetmemo.bio/drug/hicm-188-allogeneic-ipsc-cardiomyocytes#upco
 ming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245069-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0724506
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Heart Failure.\nS
 tudy: Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anth
 racycline Chemotherapy in Breast Cancer Patients\nEstimated primary comple
 tion: November 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07245069
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05194111-528@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Entresto (Sacubitril/valsartan): Phase 1/2 readout est. (NCT0519411
 1)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 1/2\, Heart Failure.\nS
 tudy: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril
 /Valsartan\nEstimated primary completion: 30 November 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05194111
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583446-603@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Istaroxime: Phase 2/3 readout est. (NCT07583446)
DESCRIPTION:Istaroxime\, phase 2/3\, Heart Failure.\nStudy: Randomized Eval
 uation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic 
 Shock\nEstimated primary completion: December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/istaroxime#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07583446
URL:https://assetmemo.bio/drug/istaroxime#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217302-314@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06217302)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Heart Failure.\nStudy: Sotag
 liflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes a
 nd Diabetic Kidney Disease\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sotagliflozin-inpefa#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06217
 302
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123779-234@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:HS235: Phase 1/2 readout est. (NCT07123779)
DESCRIPTION:HS235\, phase 1/2\, Heart Failure.\nStudy: HS235 Study in Overw
 eight and Obese Participants With Combined Pre and Post-Capillary Pulmonar
 y Hypertension Due to Heart Failure With Preserved Ejection Fraction\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hs235#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07123779
URL:https://assetmemo.bio/drug/hs235#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025629-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0702562
 9)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Dapagliflozin for Cardio-renal Protection After ICU Discharge\nEstim
 ated primary completion: 15 January 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07025629
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935370-369@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT06935370)
DESCRIPTION:Vicadrostat\, phase 3\, Heart Failure.\nStudy: A Study to Test 
 Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps Pe
 ople With Heart Failure and a Weak Pumping Function of the Left Side of th
 e Heart\nEstimated primary completion: 4 February 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06935370
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207811-634@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:Coramitug: Phase 3 readout est. (NCT07207811)
DESCRIPTION:Coramitug\, phase 3\, Heart Failure.\nStudy: CLEOPATTRA: A Rese
 arch Study to Look at the Effects of Treatment With a Medicine Called Cora
 mitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amy
 loid (ATTR) Amyloidosis\nEstimated primary completion: 29 June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/coramitug#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07207811
URL:https://assetmemo.bio/drug/coramitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643818-591@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 2 readout est. (
 NCT07643818)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 2\, Heart F
 ailure.\nStudy: Intravenous Iron to Improve Symptoms\, Quality of Life and
  Exercise Capacity in HFpEF With Iron Deficiency\nEstimated primary comple
 tion: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ferr
 ic-derisomaltose#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07643818
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082063-314@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Sotagliflozin (Inpefa): Phase 3 readout est. (NCT06082063)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 3\, Heart Failure.\nStudy: Multi
 factorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
 \nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06082063
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082063-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT06082063)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Multif
 actorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes\
 nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06082063
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714085-587@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290820
DTEND;VALUE=DATE:20290821
SUMMARY:Verquvo (Vericiguat): Phase 2/3 readout est. (NCT05714085)
DESCRIPTION:Verquvo (Vericiguat)\, phase 2/3\, Heart Failure.\nStudy: Effic
 acy\, Safety\, and Pharmacokinetics of Vericiguat in Pediatric Participant
 s With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242
 -036)\nEstimated primary completion: 20 August 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vericiguat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05714085
URL:https://assetmemo.bio/drug/vericiguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07761117-148@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20290903
DTEND;VALUE=DATE:20290904
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07761117)
DESCRIPTION:elecoglipron\, phase 3\, Heart Failure.\nStudy: A Study to Inve
 stigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Parti
 cipants With HFpEF or HFmrEF\nEstimated primary completion: 3 September 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07761117
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00610051-618@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:alprostadil: Phase 3 readout est. (NCT00610051)
DESCRIPTION:alprostadil\, phase 3\, Heart Failure.\nStudy: ALP-1 Continuous
  Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Fai
 lure\nEstimated primary completion: November 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alprostadil#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT00610051
URL:https://assetmemo.bio/drug/alprostadil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188805-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07188805)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Well Finerenone Works\, How Safe it is\, and How
  it Moves Into\, Through\, and Out of the Body Compared to Placebo When Ta
 ken With Standard Treatment in Children With Heart Failure and Left Ventri
 cular Systolic Dysfunction\nEstimated primary completion: 30 November 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07188805
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-306@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0667706
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Phase III Study Investigating Heart Failure and Cardiovascular Death
  With Baxdrostat in Combination With Dapagliflozin\nEstimated primary comp
 letion: 17 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06677060
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-525@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06677060)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Heart Failure.\nStudy: Phase 
 III Study Investigating Heart Failure and Cardiovascular Death With Baxdro
 stat in Combination With Dapagliflozin\nEstimated primary completion: 17 D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdros
 tat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06677060
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-314@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sotagliflozin (Inpefa): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Sotagliflozin (Inpefa)\, phase 2\, Heart Failure.\nStudy: Preci
 sion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimate
 d primary completion: 31 December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/sotagliflozin-inpefa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594145-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 2 readout est. (NCT07594145)
DESCRIPTION:Kerendia (Finerenone)\, phase 2\, Heart Failure.\nStudy: Precis
 ion T1D Platform - New Therapies for Cardio-Renal Complications\nEstimated
  primary completion: 31 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/finerenone#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07594145
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575672-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07575672)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Finere
 none in Patients Undergoing Transcatheter Aortic Valve Implantation With H
 eart Failure\nEstimated primary completion: 31 December 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07575672
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839585-534@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20300108
DTEND;VALUE=DATE:20300109
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07839585)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Heart Failure.\nStudy: A Cl
 inical Study of Sotatercept (MK-7962) in People With Combined Postcapillar
 y and Precapillary Pulmonary Hypertension and Heart Failure With Preserved
  Ejection Fraction (MK-7962-041)\nEstimated primary completion: 8 January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0783958
 5
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270367-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07270367)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: Finere
 none and Cardiac Remodeling\nEstimated primary completion: December 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/finerenone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07270367
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192952-661@assetmemo.bio
DTSTAMP:20261121T004019Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Kerendia (Finerenone): Phase 3 readout est. (NCT07192952)
DESCRIPTION:Kerendia (Finerenone)\, phase 3\, Heart Failure.\nStudy: A Stud
 y to Learn More About How Safe Finerenone is\, When it is Taken for a Long
 er Time With Standard Treatment\, in Children and Young Adults With Heart 
 Failure and Left Ventricular Systolic Dysfunction\nEstimated primary compl
 etion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/finerenone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07192952
URL:https://assetmemo.bio/drug/finerenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
